Interestingly, PDL1 was highly expressed in NPC and regulated by hypermethylated MIR152 and MIR34b, indicating the potential for immunotherapy using agents mimicking miR-152 or miR-34 to inhibit PD-L1 and enhance T cell proliferation and effector cytokines. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.